Clinical Trials List
2019-12-01 - 2020-05-12
Phase II
Terminated1
ICD-10C82.00
Follicular lymphoma grade I, unspecified site
ICD-10C82.09
Follicular lymphoma grade I, extranodal and solid organ sites
ICD-10C82.10
Follicular lymphoma grade II, unspecified site
ICD-10C82.19
Follicular lymphoma grade II, extranodal and solid organ sites
ICD-10C82.20
Follicular lymphoma grade III, unspecified, unspecified site
ICD-10C82.29
Follicular lymphoma grade III, unspecified, extranodal and solid organ sites
ICD-10C82.30
Follicular lymphoma grade IIIa, unspecified site
ICD-10C82.39
Follicular lymphoma grade IIIa, extranodal and solid organ sites
ICD-10C82.40
Follicular lymphoma grade IIIb, unspecified site
ICD-10C82.49
Follicular lymphoma grade IIIb, extranodal and solid organ sites
ICD-10C82.50
Diffuse follicle center lymphoma, unspecified site
ICD-10C82.59
Diffuse follicle center lymphoma, extranodal and solid organ sites
ICD-10C82.60
Cutaneous follicle center lymphoma, unspecified site
ICD-10C82.69
Cutaneous follicle center lymphoma, extranodal and solid organ sites
ICD-10C82.80
Other types of follicular lymphoma, unspecified site
ICD-10C82.89
Other types of follicular lymphoma, extranodal and solid organ sites
ICD-10C82.90
Follicular lymphoma, unspecified, unspecified site
ICD-10C82.99
Follicular lymphoma, unspecified, extranodal and solid organ sites
ICD-10Z51.12
Encounter for antineoplastic immunotherapy
ICD-9202.00
Nodular lymphoma, unspecified site, extranodal solid organ sites
-
Trial Applicant
NOVARTIS (TAIWAN) CO., LTD.
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/04/01
Investigators and Locations
Co-Principal Investigator
The Actual Total Number of Participants Enrolled
0 Terminated
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
2-4 participants
-
Global
113 participants
